Recent genomic studies have identified a series of recurrent somatic mutations in patients with myeloid malignancies, including myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), and acute myeloid leukemia (AML). Notably, these mutations frequently occur in epigenetic regulator genes such as EZH2, ASXL1, and DNMT3A. Concurrent deletion of EZH2 alone was enough to induce myelodysplasia and markedly accelerated the development of myelodysplastic disorders including both MDS and MPN. Comprehensive genome-wide analyses in hematopoietic progenitor cells revealed that upon deletion of EZH2, key developmental regulator genes were kept transcriptionally repressed, suggesting compensation by EZH1, whereas a cohort of oncogenic direct and indirect polycomb targets became derepressed. Our findings provide the first evidence of the tumor suppressor function of EZH2 in myeloid malignancies and highlight the cooperative effect of concurrent mutations in the pathogenesis of myelodysplastic disorders.
is frequently involved in chromosomal abnormalities such as -7 and 7q-, and inactivating mutations of \textit{EZH2} have also been identified in patients with MDS, MPN, and CMML— all clonal myeloid disorders originating from hematopoietic stem cells (HSCs; Ernst et al., 2010; Nikoloski et al., 2010). Of interest, other components of PRC2, \textit{EED} and \textit{SUZ12}, appeared to be mutated in a manner similar to \textit{EZH2}, although the frequencies of their mutations are much lower than those of \textit{EZH2} mutations. The PRC2-related gene \textit{ASXL1}, which plays an important role in the recruitment and/or stability of PRC2 (Abdel-Wahab et al., 2012), has also been shown to carry inactivating mutations in patients with MDS, MPN, and CMML (Abdel-Wahab et al., 2011; Bejar et al., 2011).

catalyzes di- and tri-methylation of histone H3 at lysine 27 (H3K27me3). Canonical PRC1 contains four core subunits, PCGF (which can include BMI1 or MEL18), CBX, PHC, and RING1A or RING1B, which monoubiquitylates histone H2A at lysine 119 (H2AK119ub1). PRC1 and PRC2 cooperatively function as transcriptional repressors via establishing these repressive histone modifications. PcG genes have been implicated in the maintenance of self-renewing somatic and cancer stem cells (Konuma et al., 2010; Sauvageau and Sauvageau, 2010) and have typically been characterized as oncogenes, as exemplified by somatic activating mutations of \textit{EZH2} in follicular and diffuse large B cell lymphomas (Morin et al., 2010). However, \textit{EZH2}, which is located at chromosome 7q36,
Although these mutations suggest a tumor suppressor function of PRC2-related genes in these diseases, both the impact of each PcG mutation and its interplay with coinciding mutations remain largely unknown.

Loss-of-function mouse models of Tet2, Dnmt3a, and Bap1, as well as gain-of-function mouse models of IDH1, have been reported to recapitulate some aspects of malignancies (Moran-Crusio et al., 2011; Challen et al., 2012; Dey et al., 2012; Sasaki et al., 2012). However, the role of PcG-related mutants has not yet been tested in mice. To understand the contribution of inactivating PcG mutations to the development of myeloid malignancies, we examined the Ezh2-deficient mice over longer periods of time and also tested the impact of concurrent depletion of Ezh2 and Tet2 on hematopoiesis.

RESULTS

Somatic mutations of PcG genes in myeloid dysplasia

In our cohort of 119 patients with myelodysplastic disorders, which includes MDS, CMML, and AML with myelodysplasia-related changes (AML/MRC), inactivating mutations in EZH2 and ASXL1 were detected in 8.4 and 16.8% of patients, respectively. Moreover, 3.4% of patients had deletion of EZH2 (located at 7q36) associated with -7 and 7q- chromosomal abnormalities (Fig. 1 A and Table S1). Notably, 57.1% of these EZH2 mutations coexisted with TET2 mutations. Conversely, 34.8% of patients with TET2 mutations had coexisting EZH2 mutations (Fig. 1 B). These findings suggest a link between EZH2 and TET2 mutations in the pathogenesis of myelodysplastic disorders.

Deletion of Ezh2 results in enhanced repopulating capacity of HSCs and promotes myeloid-biased repopulation

To decipher the pathological role of inactivating EZH2 mutations and concurrent inactivation of EZH2 and TET2 genes in malignant stem cell disorders, we crossed Cre-ERT;Ezh2−/− mice (Mochizuki-Kashio et al., 2011) and Tet2 gene trap mice (Tet2KD/KD, Shide et al., 2012). Tet2KD/KD mice, in which the gene trap vector is inserted into exon 2 of Tet2 just before the first coding exon, express Tet2 mRNA at levels ~20% of those of the WT mice and frequently die by postnatal day 3 (Shide et al., 2012). Considering the early death of Tet2KD/KD mice and a necessity to exclude the influence of the loss of Tet2 and Ezh2 in BM niche cells, we transplanted E14.5 fetal liver cells from Cre-ERT control (WT), Cre-ERT;Tet2KD/KD, Cre-ERT; Ezh2−/−, and Cre-ERT;Tet2KD/KD/Ezh2−/− CD45.2 mice into lethally irradiated CD45.1 recipient mice and deleted Ezh2 by intraperitoneal injection of tamoxifen at 4 wk after transplantation (Fig. 2 A). We hereafter refer to the recipient mice reconstituted with Tet2KD/KD, Ezh2Δ/Δ, and Tet2KD/KD/Ezh2Δ/Δ cells as Tet2KD/KD, Ezh2Δ/Δ, and Tet2KD/KD/Ezh2Δ/Δ mice, respectively. EZH2 is a catalytic component of PRC2 that catalyzes the methylation of H3K27. As expected, the levels of H3K27me3 were markedly reduced upon deletion of Ezh2 in both Lineage+‘Sca-1’c-Kit+’ (LSK) cells, which include HSCs and multipotent progenitor cells (MPPs), and in granulocyte-macrophage progenitors (GMPs; Fig. 2 B). TET2, a methylcytochrome oxygenase, catalyzes the oxidation of 5-mC (5-methylcytosine) to 5-hmC (5-hydroxymethyl cytosine), the first step of active demethylation ((Ernst et al., 2010; Ko et al., 2010). The levels of 5-hmC in total BM cells were also reduced in Tet2KD/KD and Tet2KD/KD/Ezh2Δ/Δ cells, whereas there was no obvious
Indeed, LSK cells of all genotypes established significantly higher chimerism in the BM LSK fraction compared with WT LSK cells (Fig. 3 C). All mutant cells taken from the primary recipients continued to propagate in the secondary recipients during serial transplantation and exhibited myeloid–biased differentiation (Fig. 3 D). These results reveal that the loss of Ezh2 augments the repopulating capacity of HSCs and activates the production of myeloid cells in much the same way as the loss of Tet2 does.

**Deletion of Ezh2 causes myeloid dysplasia in mice**

We next analyzed the hematopoiesis in recipient mice reconstituted with Tet2<sup>KD/KD</sup>, Ezh2<sup>2A/2A</sup>, and Tet2<sup>KD/KD</sup>Ezh2<sup>2A/2A</sup> hematopoietic cells. (A) PB cell counts in recipients reconstituted with Tet2<sup>KD/KD</sup>, Ezh2<sup>2A/2A</sup>, and Tet2<sup>KD/KD</sup>Ezh2<sup>2A/2A</sup> fetal liver hematopoietic cells at 12 wk after deletion of Ezh2. White blood cell (WBC), hemoglobin (Hb), and platelet (Plt) counts in the PB from WT (n = 19), Tet2<sup>KD/KD</sup> (n = 23), Ezh2<sup>2A/2A</sup> (n = 13), and Tet2<sup>KD/KD</sup>Ezh2<sup>2A/2A</sup> (n = 23) mice are plotted as dots and the mean values are indicated as bars. (B) The hematopoietic compartment of the PB assessed by manual differential cell counts, performed at 12 wk after deletion of Ezh2. WT (n = 5), Tet2<sup>KD/KD</sup> (n = 7), Ezh2<sup>2A/2A</sup> (n = 5), and Tet2<sup>KD/KD</sup>Ezh2<sup>2A/2A</sup> (n = 6) mice are represented as mean ± SEM. Arrowheads indicate statistically significant populations compared with WT (P < 0.05). (C) Smear preparation of PB from WT, Tet2<sup>KD/KD</sup>, Ezh2<sup>2A/2A</sup>, and Tet2<sup>KD/KD</sup>Ezh2<sup>2A/2A</sup> mice at 12 wk after deletion of Ezh2 observed after May-Giemsa staining. Bar, 10 µm. Hyposegmented neutrophils consistent with a pseudo Pelger-Huët anomaly (bottom right), hypersegmented neutrophils (bottom left), and dysplastic monocyte (top right) are depicted in insets. Bar, 5 µm. (D) BM analysis of WT, Tet2<sup>KD/KD</sup>, Ezh2<sup>2A/2A</sup>, and Tet2<sup>KD/KD</sup>Ezh2<sup>2A/2A</sup> mice at 12 wk after deletion of Ezh2. Absolute numbers of total BM cells from a unilateral pair of the femur and the tibia of WT (top right) are depicted in insets. Bar, 5 µm. Hyposegmented neutrophils consistent with a pseudo Pelger-Huët anomaly (bottom right), hypersegmented neutrophils (bottom left), and dysplastic monocyte (top right) are depicted in insets. Bar, 10 µm. Hyposegmented neutrophils consistent with a pseudo Pelger-Huët anomaly (bottom right), hypersegmented neutrophils (bottom left), and dysplastic monocyte (top right) are depicted in insets. Bar, 10 µm.

To explore the consequence of loss of Ezh2 and/or Tet2 in hematopoietic stem/progenitor cells, we first performed competitive repopulating assays using LSK cells recovered from the recipient mice at 3 mo after deletion of Ezh2. It has been reported that Tet2 loss leads to increased HSC self-renewal and myeloid transformation (Moran-Crusio et al., 2011; Shide et al., 2012). As expected, Tet2<sup>KD/KD</sup> LSK cells readily established progressively increasing chimerism in the PB over time (Fig. 3 A). Similarly, the contribution of Ezh2<sup>2A/2A</sup> and Tet2<sup>KD/KD</sup>Ezh2<sup>2A/2A</sup> LSK-derived cells to the myeloid compartment of the PB increased over time, although the total chimerism was lower than that of Tet2<sup>KD/KD</sup> cells because of inefficient production of lymphocytes by Ezh2-deficient LSK cells (Fig. 3, A and B). Indeed, LSK cells of all genotypes established significantly higher chimerism in the BM LSK fraction compared with WT LSK cells (Fig. 3 C). All mutant cells taken from the primary recipients continued to propagate in the secondary recipients during serial transplantation and exhibited myeloid–biased differentiation (Fig. 3 D). These results reveal that the loss of Ezh2 augments the repopulating capacity of HSCs and activates the production of myeloid cells in much the same way as the loss of Tet2 does.

**Deletion of Ezh2 causes myeloid dysplasia in mice**

We next analyzed the hematopoiesis in recipient mice reconstituted with Tet2<sup>KD/KD</sup>, Ezh2<sup>2A/2A</sup>, and Tet2<sup>KD/KD</sup>Ezh2<sup>2A/2A</sup> cells. PB from Ezh2<sup>2A/2A</sup> and Tet2<sup>KD/KD</sup>Ezh2<sup>2A/2A</sup> mice at 3 mo after deletion of Ezh2 showed reduced white blood cell counts due to lymphopenia and increased platelet counts. In addition, mild but significant anemia was detected in these mice (Fig. 4, A and B).
**Ezh2** mice showed monocytosis in PB as reported previously (Moran-Crusio et al., 2011), whereas **Tet2** mice did not (Fig. 4 B). Cytological analysis of Ezh2 mice revealed morphological abnormalities in myeloid cells, such as delayed maturation of neutrophils, hypersegmented neutrophils, and dysplasia of monocytes (Fig. 4 C). This trend was more evident in **Tet2** mice compared with Ezh2 mice but was not obvious in **Tet2** PB (Fig. 4 C).

BM analysis at 3 mo after deletion of Ezh2 revealed that although total BM cell numbers were mildly increased only in **Tet2** mice, all mutant mice had a greater proportion of LSK cells than the WT mice (Fig. 4 D). Similarly, **Tet2** mice, Ezh2, and **Tet2** mice had a greater proportion of common myeloid progenitors (CMPs) and/or MEPs (Fig. 4 D). Furthermore, extramedullary hematopoiesis was evident in the spleen of all mutant mice as defined by a significant increase in the absolute number of LSK cells and myeloid progenitors, although splenomegaly was evident only in **Tet2** mice, likely because of impaired lymphopoiesis in the absence of Ezh2 (Fig. 4 E).

**Ezh2** and **Tet2** mice develop myelodysplastic disorders

During a long observation period, we found that not only **Tet2** mice but also Ezh2 mice die of hematological disorders. This is the first study to describe the lethal hematopoietic phenotypes caused by loss of Ezh2. **Tet2** mice developed CMPML-like disease accompanied by monocytosis and extramedullary hematopoiesis as reported previously (Moran-Crusio et al., 2011) and half of the mice died by 10 mo after transplantation. Notably, Ezh2 mice also developed MDS/MPN-like disease and half of the mice died by 10 mo after transplantation (Fig. 5 A and Table S2). They showed myelo-proliferative features characterized by active extramedullary...
hematopoiesis in the spleen as evident from splenomegaly with a marked increase in LSK cells and MEPs resulting in effacement of lymphoid follicles (Fig. 5, B–D). They also showed a significant increase in LSK cells and MEPs in the BM, whereas they did not show obvious monocytosis in the PB (Fig. 5, E and F; and Table S2). They were anemic and showed increased apoptosis in Ter119<sup>high</sup>CD71<sup>high</sup> erythroblasts (Fig. 5 G) and LSK cells (Fig. 6 E) in the BM, suggesting ineffective erythropoiesis, a feature compatible with myelodysplastic disorders. Ezh2<sup>2A/Δ</sup> mice also showed dysplasia of myeloid cells as described above (Fig. 4 C).

To our surprise, concurrent deletion of Tet2 and Ezh2 significantly shortened the latency of disease development and all Tet2<sup>2K/D</sup>Ezh2<sup>2A/Δ</sup> mice died by 10 mo after transplantation (Fig. 5 A). Histological analysis of moribund Tet2<sup>2K/D</sup>Ezh2<sup>2A/Δ</sup> mice revealed lethal pneumonia in all mice analyzed (n = 6; unpublished data). Tet2<sup>2K/D</sup>Ezh2<sup>2A/Δ</sup> mice developed heterogeneous diseases which were classified into two types of myeloid neoplasms: (1) MDS/MPN including CMMML (n = 8) and (2) MDS (n = 6; Table S2). MDS/MPN mice showed myeloproliferative features, including CMMML-like monocytosis in the PB (Fig. 6 A and Table S2) and/or splenomegaly with extramedullary hematopoiesis (Fig. 6 B), and an increase in LSK cells in the BM (Fig. 6 C). In contrast, MDS mice did not show obvious myeloproliferative features but showed a trend of pancytopenia (Fig. 6 A and Table S2). Myeloid dysplasia, including delayed maturation of neutrophils, a pseudo Pelger-Huët anomaly, hypersegmented neutrophils, and dysplasia of monocytes, was evident in Tet2<sup>2K/D</sup>Ezh2<sup>2A/Δ</sup> mice compared with Tet2<sup>2A/Δ</sup> and Ezh2<sup>2A/Δ</sup> mice as described above (Fig. 4 C).

Furthermore, MDS and MDS/MPN mice had a lower proportion of Ter119<sup>+</sup> erythroblasts compared with WT mice (unpublished data). The proportion of Annexin V<sup>+</sup> cells in LSK cells from the indicated mice at 8 mo after transplantation showed mean ± SEM from three independent experiments (WT, n = 3; MDS/MPN, n = 2; MDS, n = 2). (D) Percentage of Annexin V<sup>+</sup> cells in LSK cells from the indicated mice at 8 mo after transplantation shown as mean ± SEM from three independent experiments (WT, n = 3; Tet2<sup>2K/D</sup>, n = 3; Ezh2<sup>2A/Δ</sup>, n = 3; and Tet2<sup>2K/D</sup>Ezh2<sup>2A/Δ</sup>, n = 3). * P < 0.05; ** P < 0.01; *** P < 0.001.

Alterations in expression of Ezh1 target genes associated with disease progression

To elucidate the changes in gene expression responsible for the hematological phenotypes induced by loss of Ezh2 and/or Tet2, we performed microarray analysis using LSK cells and GMPs from each mutant mouse at 3 mo after deletion of Ezh2 and MDS/MPN and MDS mice. Of interest, there was significant overlap between genes up-regulated or down-regulated in Tet2<sup>2K/D</sup> and Ezh2<sup>2A/Δ</sup> LSK cells. This was true among all genotypes and diseases, and the overall gene expression profiles were highly correlated with each other (Fig. 7). To better
understand the consequences of the loss of Ezh2 and/or Tet2, we next performed gene set enrichment analysis (GSEA; Subramanian et al., 2005). Embryonic stem (ES) cell–like signatures, which have been widely used in assessment of cancer gene signatures, are subdivided into a PRC module, a Myc module, and a core ES module (Kim et al., 2010). Among these, the Myc module, which is active in various cancers and predicts cancer outcome, was significantly enriched in Ezh2Δ/Δ LSK cells and became highly enriched in Tet2ΔKD/KD Ezh2Δ/Δ LSK cells during the development of MDS/MPN and MDS (Fig. 8 A). Of note, the Myc module became enriched in LSK cells but not in GMPs, suggesting the existence of pathological stem cells in the LSK fraction. Several modules related to enhanced cell cycle were also positively enriched in MDS/MPN and MDS LSK cells (unpublished data). We next analyzed gene sets of Ezh2 targets that lose H3K27me3 upon deletion of Ezh2 in ES cells (ES_Ezh2 targets) and Ezh1 targets profiled in ES cells (ES_Ezh1 targets; Shen et al., 2008). As expected, all of the PRC2 gene sets showed a trend of positive enrichment (derepression) in Ezh2Δ/Δ and Tet2ΔKD/KD Ezh2Δ/Δ LSK cells and GMPs (Fig. 8 A). Notably, however, Ezh1 targets were negatively enriched (repressed) and the degree of positive enrichment of Ezh2 targets was attenuated in Tet2ΔKD/KD Ezh2Δ/Δ LSK cells from mice which developed myelodysplastic disorders. These data suggest compensatory action by Ezh1 in LSK cells during the development of myelodysplastic disorders. Of interest, both the Ezh1 and Ezh2 targets were positively enriched even in Tet2ΔKD/KD LSK cells, suggesting some involvement of Tet2 in PRC2-mediated gene silencing in HSC/MPPs.

Alterations in H3K27me3 upon deletion of Ezh2

To assess the genome-wide effects of loss of Ezh2 and/or Tet2 on epigenome, we conducted chromatin immunoprecipitation sequencing (ChIP-seq) for H3K27me3 in hematopoietic cells from WT, Tet2ΔKD/KD, Ezh2Δ/Δ, and Tet2ΔKD/KD Ezh2Δ/Δ mice at 4 mo after transplantation. Due to the paucity of LSK HSC/MPPs, we used GMPs for ChIP-seq analysis and characterized the H3K27me3 levels over the region from 5.0 kb upstream to 0.5 kb downstream of transcriptional start sites (TSSs) of Reference Sequence (RefSeq) genes (Pruitt et al., 2007). As expected, drastic reductions in the levels of H3K27me3 were observed in GMPs from Ezh2Δ/Δ and Tet2ΔKD/KD Ezh2Δ/Δ mice, although considerable levels of H3K27me3 remained even in the absence of Ezh2 (Fig. 8 B). Among PcG targets (greater than fourfold enrichment of H3K27me3 compared with input in WT GMPs) that showed greater than twofold reduction of H3K27me3 levels in Tet2ΔKD/KD Ezh2Δ/Δ GMPs, 121 genes were derepressed greater than twofold in both MDS/MPN and MDS LSK cells compared with WT. These genes included 24 potential oncogenes such as Hmg2 (Oguro et al., 2012), Pbx3 (Li et al., 2013), and Lmo1 (Tremblay et al., 2010; Table S3).

Surprisingly, H3K27me3 marks around TSSs became more enriched (greater than onefold compared with WT) in a small portion of genes upon deletion of Ezh2, particularly in Ezh2Δ/Δ GMPs (Fig. 8, B–D), suggesting a major role for Ezh1 on these gene promoters. Indeed, these genes overlapped considerably with the targets of Ezh1 in ES cells (Shen et al., 2008; Fig. 8 E), and this trend was more obvious with genes that showed high levels of H3K27me3 (>35-fold enrichment of H3K27me3 compared with input in Ezh2Δ/Δ GMPs). More importantly, the genes that maintained H3K27me3 levels upon deletion of Ezh2 were overlapped markedly with genes marked with bivalent histone domains in ES cells (Bernstein et al., 2006; Ku et al., 2008; Fig. 8 F). This trend was again more obvious with the 124 genes that showed high levels of H3K27me3 (>35-fold enrichment of H3K27me3 in Ezh2Δ/Δ GMPs), and most of these genes appeared to be canonical developmental regulators, including genes encoding homeobox, paired-box, T-box, forkhead, and Gata family transcription factors and zinc finger DNA-binding proteins (Table S4). Because the amounts of DNA immunoprecipitated from Ezh2Δ/Δ and Tet2ΔKD/KD Ezh2Δ/Δ GMPs are less than those from WT and Tet2ΔKD/KD GMPs, we
MPN-like disease in mice, similar to the depletion of Tet2. Ezh2\(^{-/-}\) mice developed a lethal MDS/MPN-like disease with myeloproliferative features, including enhanced repopulating capacity of HSCs and extramedullary hematopoiesis in the spleen, and myelodysplastic features, such as anemia accompanied by enhanced apoptosis in erythroblasts and dysplasia in myeloid cells. These findings are compatible with the recurrent inactivation of EZH2 genes in myelodysplastic disorders and strongly support the tumor suppressor function of Ezh2.

**DISCUSSION**

In this study, we first demonstrated that the deletion of Ezh2 confers a growth advantage to HSCs and results in an MDS/MPN-like disease in mice, similar to the depletion of Tet2. Ezh2\(^{-/-}\) mice developed a lethal MDS/MPN-like disease with myeloproliferative features, including enhanced repopulating capacity of HSCs and extramedullary hematopoiesis in the spleen, and myelodysplastic features, such as anemia accompanied by enhanced apoptosis in erythroblasts and dysplasia in myeloid cells. These findings are compatible with the recurrent inactivation of EZH2 genes in myelodysplastic disorders and strongly support the tumor suppressor function of Ezh2.

**Figures 8.** Alterations in gene expression and H3K27me3 levels upon deletion of Ezh2. (A) Gene expression alterations associated with disease progression. Normalized enrichment score (NES) from overall gene expression profiles of LSK cells and GMPs derived from GSEA is shown as the number in each cell. Red and blue colors represent positive (up-regulated in the given genotype relative to WT) and negative (up-regulated in WT relative to the given genotype) enrichment, respectively. Concentrated colors show that the nominal p-value is <0.05 and false discovery rate (FDR) is <0.05, which suggests meaningful enrichment for the given gene sets. Pale colors show borderline enrichment. The cells which do not meet these criteria show white color. (B) Summary of H3K27me3 enrichment detected by ChIP-seq analysis. GMPs isolated from primary recipient mice at 4 mo after transplantation were subjected to ChIP-seq analysis using an anti-H3K27me3 antibody. The fold enrichment values of H3K27me3 signals were calculated against the input signals (ChIP/input) from 5.0 kb upstream to 0.5 kb downstream of the TSS of RefSeq genes. The red boxes indicate genes with the H3K27me3 enrichment >35-fold in Ezh2\(^{-/-}\) and Tet2\(^{K/D}\) Ezh2\(^{-/-}\) GMPs. (C) Scatter plots of H3K27me3 enrichment in Tet2\(^{K/D}\), Ezh2\(^{K/D}\), and Tet2\(^{K/D}\) Ezh2\(^{-/-}\) GMPs in comparison with that in WT GMPs. Gray lines indicate 35-fold enrichment, which is the value defined as high enrichment in A. The numbers of genes with higher and lower fold enrichment than that of WT (divided by red lines) are indicated. (D) Scatter plots of 124 genes enclosed by a red square in B showing the H3K27me3 enrichment >35-fold relative to WT in Ezh2\(^{-/-}\) and Tet2\(^{K/D}\) Ezh2\(^{-/-}\) GMPs. Gray lines indicate 1.0, which is the value indicating that Ezh2\(^{-/-}\) and Tet2\(^{K/D}\) Ezh2\(^{-/-}\) GMPs showed the same fold enrichment as WT. (E and F) The proportion of Ezh1 target genes (E) and genes that are marked with univalent (H3K4me3 or H3K27me3) or bivalent histone domains (H3K4me3 and H3K27me3; F) identified in ES cells were categorized by the changes in H3K27me3 levels in Ezh2\(^{K/D}\) GMPs. The proportions in all RefSeq genes are shown in the first lane. PRC2 target genes were subdivided into genes with reduced H3K27me3 levels (<0.5-fold compared with WT), genes that maintained H3K27me3 levels (>1-fold compared with WT), and genes with the H3K27me3 enrichment >35-fold compared with input in Ezh2\(^{K/D}\) GMPs in B.
of EZH2. Although no mutations have been identified in PRC1 genes, we recently reported that concurrent loss of the PRC1 gene Bmi1 along with Ink4a/Arf in mice causes pathological hematopoiesis that mimics human primary myelofibrosis, a disease categorized as an MPN (Oguro et al., 2012). Together, inactivation of PcG genes could contribute to the pathogenesis of malignant stem cell disorders.

We further demonstrated that inactivating Ezh2 and TET2 mutations coexist in 6.7% of patients with myelodysplastic disorders, and concurrent deletion of Ezh2 and Tet2 in mice accelerates the development of heterogeneous myelodysplastic disorders including MDS and MDS/MPN. Of note, Tet2<sup>KD/KD</sup>Ezh2<sup>Δ/Δ</sup> mice showed more advanced myelodysplastic features compared with Tet2<sup>KD/KD</sup> and Ezh2<sup>Δ/Δ</sup> mice. This is the first study to describe the cooperative effects of the independent mutations in the pathogenesis of myelodysplastic disorders. Extensive mutation analyses of the myeloid malignancies have revealed that most MDS and MDS/MPN patients have several concurrent genetic mutations, but their pathological meanings remain to be addressed. Our findings highlight the cooperative effects of the independent mutations in the pathogenesis of myelodysplastic disorders. It is assumed that the deregulated gene expression upon concurrent depletion of Tet2 and Ezh2 accounts for enhancement in the

Figure 9. The levels of H3K27me3 at promoter regions in GMPs. Visualization of ChIP-seq data of the H3K27me3 levels of several developmental regulator genes (Hoxd locus, Gata4, and Pox5), tumor suppressor genes (Cdkn2a and Cdkn2b) and oncogenes (Hmg2 and Pbx3) in GMPs from WT, Tet2<sup>KD</sup>, Ezh2<sup>Δ/Δ</sup>, and Tet2<sup>KD</sup>Ezh2<sup>Δ/Δ</sup> mice at 4 mo after transplantation using the Integrative Genomics Viewer (IGV). Schematic diagram of these gene loci indicates their genomic structures. Exons and untranslated regions are demarcated by large and small black boxes, respectively. Data of ChIP analyses at the promoters of selected genes are also depicted. Quantitative ChIP analyses of GMPs from WT and Ezh2<sup>Δ/Δ</sup> mice at 6 mo after transplantation were performed. The relative amounts of immunoprecipitated DNA are depicted as a percentage of input DNA. N.D. indicates not detected. The data are shown as the mean ± SEM for triplicate analyses. Regions amplified from the precipitated DNA by site-specific quantitative PCR are indicated by arrows. *, P < 0.05.
myelodysplastic features, such as dysplasia of myeloid cells, functional defects in neutrophils, and enhanced apoptosis in erythroblasts, although these studies require further investigation. On the contrary, EZH2 mutations are very rare in de novo AML and chronic myeloid leukemia in blastic transformation (CML-BC; Ernst et al., 2010; Chung et al., 2012; Raza and Galili, 2012; Shih et al., 2012), and MDS patients with EZH2 mutations have much lower risk of transformation to AML compared with those with other gene mutations (Chung et al., 2012; Raza and Galili, 2012; Shih et al., 2012). Indeed, no Ezh2Δ/Δ and Tet2Δ/KD/Ezh2Δ/Δ mice developed AML in this study. We and other groups have previously reported that deletion of Ezh2 largely attenuates the leukemogenicity of AML in a mouse model (Neff et al., 2012; Tanaka et al., 2012). These findings suggest differential roles of EZH2 in AML versus MDS and MDS/MPN.

Although deletion of Ezh2 results in a drastic reduction in H3K27me3 levels, considerable levels of H3K27me3 are retained. The genes that maintained H3K27me3 levels after loss of Ezh2 largely overlap with the targets of Ezh1 in ES cells, and most of these genes are developmental regulator genes that are marked with bivalent histone domains (Bernstein et al., 2006; Ku et al., 2008). Furthermore, tumor suppressor genes such as Ink4a/Arf, a critical PcG target for the maintenance of the self-renewal capacity of HSCs (Oguro et al., 2006), and PcG-targeted developmental regulator genes, such as Pax5 (Oguro et al., 2010), were kept closely repressed by reduced but significant levels of H3K27me3 modification (Fig. 9). These findings indicate that Ezh1 is capable of repressing developmental regulator genes and tumor suppressor genes, acting to maintain pathological stem cells in the absence of Ezh2. Of interest, Ezh1 was recently reported to maintain HSCs in a slow-cycling, undifferentiated state (Hidalgo et al., 2012). Together, our findings suggest that Ezh1 plays a critical role in pathological stem cells as well as HSCs.

In contrast, several PcG targets became derepressed in Ezh2Δ/Δ and Tet2Δ/KD/Ezh2Δ/Δ LSK cells. These included many direct PcG targets that are potential oncogenes, such as Hmga2, Pbx3, and Lmo1. Furthermore, the Myc module, which is active in various cancers, was positively enriched in Ezh2Δ/Δ LSK cells and further enriched in MDS/MPN and MDS LSK cells. The derepression of PcG-targeted oncogenes in conjunction with the up-regulation of the Myc module could function as the major drivers in HSCs for the induction of myelodysplastic and myeloproliferative disorders in the absence of Ezh2.

Of interest, Ezh2 knock-in (Ezh2-KI) mice overexpressing Ezh2 specifically in hematopoietic cells develop MPN (Herrera-Merchan et al., 2012). Ezh2-KI mice show an enhanced HSC activity similarly to Ezh2Δ/Δ mice in this study. GSEA showed significant positive enrichment of the Myc module in both Ezh2Δ/Δ and Ezh2-KI LSK cells (unpublished data). However, Ezh2-KI mice do not show myelodysplastic features. Apoptosis in LSK cells is suppressed in Ezh2-KI mice but enhanced in Ezh2Δ/Δ mice. Ezh2-KI LSK cells show enhanced colony-forming capacity, whereas Ezh2Δ/Δ LSK cells show severely compromised proliferation in culture probably due to failure in the transcriptional repression of tumor suppressor genes such as p19ARF (unpublished data), as we have previously reported in transformed myeloid progenitors (Tanaka et al., 2012). These findings clearly discriminate the effects of overexpression and loss/hypomorphism of Ezh2 on hematopoiesis, even though both results in clonal propagation of HSCs.

Finally, the functional cross talk between DNA and histone modifications is an intriguing issue to understand the epigenetics of myeloid malignancies. Tet2Δ/KD/Ezh2Δ/Δ mice developed not only MDS/MPN but also MDS, whereas Ezh2Δ/Δ mice developed only MDS/MPN. Moreover, myelodysplastic features were more pronounced in Tet2Δ/KD/Ezh2Δ/Δ mice compared with Ezh2Δ/Δ mice. These findings suggest that loss of Ezh2 and Tet2 cooperate to generate a MDS phenotype in mice. However, enhanced apoptosis in the absence of Ezh2 was significantly attenuated in LSK cells, but not in erythroblasts, upon down-regulation of the Tet2 expression, suggesting an opposing impact of loss of Ezh2 and Tet2 on apoptosis in MDS-initiating hematopoietic stem and progenitor cells.

The understanding of the pathological significance of each somatic gene mutation in myeloid malignancies is just starting to be revealed. Nevertheless, our findings clearly indicate that mouse models, including our own, are capable of faithfully mimicking myelodysplastic disorders and can serve as valuable tools for the analysis of epigenomics of myelodysplastic disorders and preclinical therapeutic studies.

**MATERIALS AND METHODS**

**Sequencing analysis of primary samples with MDS and related myeloid neoplasms.** Genomic DNAs from 119 BM samples with MDS and related neoplasms were analyzed for mutations of TET2, IDH1, IDH2, EZH2, and ASXL1 genes by high-throughput sequencing of SureSelect-enriched target exons (Agilent Technologies) according to manufacturer’s protocol. Genome-wide copy number lesions were also analyzed using GeneChip SNP-genotyping microarrays (Affymetrix) as previously described (Chen et al., 2008). Allelic imbalances were detected from the allele-specific copy numbers calculated using CNAG/AcCNAR software (http://www genomewinjin.jp; Nannya et al., 2005; Yamamoto et al., 2007). All mutations were confirmed by Sanger-sequencing. All patient samples were appropriately anonymized before the analysis according to the protocol approved by the Ethics Boards of the University of Tokyo.

**Mice and generation of fetal liver chimeras.** Tet2Δ/KD and Ezh2Δ/Δ mice, which had been backcrossed at least eight times onto a C57BL/6 (CD45.2) background, were used (Mochizuki-Kashio et al., 2011; Shide et al., 2012). For conditional deletion of Ezh2, the mice were crossed with Rosa26-Cre-ERT mice (Taconic). C57BL/6 (CD45.2) mice were purchased from Japan SLC. C57BL/6 mice congenic for the Ly5 locus (CD45.1) were purchased from Sankyo-Lab Service. All experiments using the mice were performed in accordance with our institutional guidelines for the use of laboratory animals and approved by the Review Board for animal experiments of Chiba University (approval ID: 25–104). To generate fetal liver chimeras, we intravenously transplanted E14.5 fetal liver from CD45.2 mice into 8-wk-old CD45.1 recipients irradiated at a dose of 9.5 Gy. After 1 mo, the recipient mice were injected with 100 µl tamoxifen dissolved in corn oil at a concentration of 10 mg/ml intraperitoneally once a day for 5 consecutive days to induce Cre activity.

**Serial transplantation assay.** 600 CD45.2 LSK cells were sorted from the BM of the primary recipient mice reconstituted with WT, Tet2Δ/KD, Ezh2Δ/Δ,
and Ter20(−/−)/Ezh2(−/−) cells at 4 mo after transplantation and injected into lethally irradiated CD45.1 mice (secondary recipient mice) along with 4 × 10^6 BM cells (CD45.1) for competitor cells. For tertiary transplantation, 2 × 10^6 whole BM cells taken from the secondary recipient mice at 4 mo after transplantation were injected into lethally irradiated CD45.1 mice.

**Flow cytometry and antibodies.** mAbs recognizing the following antigens were used in flow cytometry and cell sorting: CD45.2 (104), CD45.1 (A20), Gr-1 (B6;8-65), CD11b/Mac-1 (M1/70), Ter-119, CD127/IL-7ra (A7R34), B220 (RA3-6B2), CD4 (L3T4), CD8α (53–6.7), CD11c/Kit (BBB), Sca-1 (D7), and CD16/32/FcγRII-III (93). The mAbs were purchased from BD, eBioscience, or BioLegend. For Annexin V staining, cells were suspended with 1× Annexin binding buffer (BD) and stained with FITC-Annexin V (BD) according to the manufacturer’s protocol. Dead cells were eliminated by staining with 1 µg/ml propidium iodide (Sigma-Aldrich). All flow cytometric analyses and cell sorting were performed on a FACSaria II or FACSCanto II (BD).

**Microarray analysis.** A one-color microarray-based gene expression analysis system (Agilent Technologies) containing 39,429 clones was used (SurePrint G3 Mouse GE 8 × 60K array; Agilent Technologies), according to the manufacturer's instructions. Total RNA was extracted from 5 × 10^6 sorted LSK cells or GMPs. A total of 10 ng of total RNA was mixed with spike-in controls using a One Color Spike Mix kit (Agilent Technologies), amplified and labeled with Cyanine 3 using a Quick Amp Labeling kit (Agilent Technologies) and a Gene Expression Wash Pack (Agilent Technologies), according to the manufacturer's instructions, which generated single-color labeled cRNA. A total of 1,650 ng of the labeled cRNA was used for each hybridization. The process of hybridization and washing was performed using an Hi-RPM Gene Expression Hybridization kit (Large; Agilent Technologies) containing 39,429 clones was used (SurePrint G3 Mouse GE 8 × 60K array; Agilent Technologies), according to the manufacturer's instructions. A total of 170,000–250,000 clusters were generated per tile, and 36 cycles of the sequencing reactions were performed. Short-read sequences were aligned to the mouse genome sequences (mm9 from University of California, Santa Cruz Genome Browser; http://genome.ucsc.edu/) using the Eland program. Sequences allowing no more than two mismatches per sequence were used for the analysis. The ChIP-Seq signal was quantified as total number of reads per million. To enumerate genes with H3K27me3 modification, genes with cumulative tag numbers in the region 5.0 kb upstream of the TSS to 0.5 kb downstream of the TSS greater than twofold was selected.

**Statistical analysis.** Heat map was drawn by Matrix2png (Pawlins and Noble, 2003). Statistical tests were performed using Prism (version 5; GraphPad Software). For analysis of survival curves, log rank (Mantel-Cox) test was performed.

**Deposition of the data.** Microarray and ChIP-sequence data were deposited in Gene Expression Omnibus (accession no. GSE42666) and DNA Data Bank of Japan (DDBJ, accession no. DRA000485–488), respectively.

**Online supplemental material.** Table S1 lists the gene mutations and abnormalities in chromosome 7 in patient samples. Table S2 provides the detailed hematological characteristics of diseased mice. Table S3 lists the potential oncogenes of direct PcG targets derepressed in the absence of Ezh2. Table S4 lists the genes with a fold enrichment of H3K27me3 >35 compared with input in Ezh2-deficient GMPs. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20131144/DC1.

We thank Terumi Horiuchi for data mining of the ChIP-seq analysis and Kazue Imai for assistance on statistical analysis.

This work was supported in part by Grants-in-aid for Scientific Research (#24249054 and #22150002), Scientific Research on Innovative Areas "Genome Science" (#22150002) and the Global COE Program (Global Center for Education and Research in Immune System Regulation and Treatment) from MEXT, Japan, a Grant-in-aid for Core Research for Evolutionary Science and Technology (CREST) from the Japan Science and Technology Corporation (JST), and grants from the Takeda Science Foundation, the Uehara Memorial Foundation, and the Tokyo Biochemical Research Foundation.

The authors have no competing financial interests to declare.

Submitted: 1 June 2013
Accepted: 15 October 2013

JEM 11 of 13

Article
REFERENCES


